Clinical Investigation

Evaluated Of Borderline Ovary Tumors: A 5-year Retrospective Analysis in a Single Center


  • Mustafa Coşan Terek
  • Levent Akman
  • Yılmaz Dikmen
  • Ahmet Aydın Özsaran
  • Seda Hurşitoğlu
  • Zeynep Elmalı
  • Osman Zekioğlu

Turk J Obstet Gynecol 2013;10(2):103-109


The purpose of this study was to evaluate the clinical and histopathologically variables, treatment modality and, recurrens in patients treated for borderline ovarian tumors (BOT).


A thirty-three patients treated for BOT were evaluated retrospectively in Ege University Medical School, Division Of Gynecologic Oncology during the 2005-2001, were evaluated retrospectively.


The average age was 41years. The average tumor size was 9,5 cm (2 – 27 cm) and histopathologic diagnose are serous, mucinous and seromucinous of BOT in 69% (23/33), 21% (7/33) müsinöz, 10% (3/33), respectively. Frozen section was performed in 32 patients (96%) and accuracy rate of frozen section was 85%. Eighteen patients underwent total abdominal hysterectomy and bilateral salpingoopherectomy, one patient total laparoscopic hysterectomy and bilateral salpingoophorectomy, two patients laparoscopic cystectomy, 4 patients cystectomy by laparotomy and 8 patients unilateral salpingoophorectomy by laparotomy. The reccurence occured in a patient who underwent salpingoophorectomy by laparotomy. Twenty-two patients had stage IA (67%), 5 had stage IB (15%), 1 had stage IC (3%), 2 had stage IIA (6%) and 1 had stage IIIB (9%) disease. The avarege follow-up time was 37 months.


BOT is usually observed in a premenopausal period and had a better prognosis than malignant tumors. The principal treatment modality of the BOT is surgery. The proposed modality of treatment must take into consideration the patients who wish to preserve fertility.

Keywords: Borderline ovary tumor, prognosis, histopathology, recurrence.